



Boston Scientific Corporation Class Action Lawsuit - BSX

Boston Scientific Corporation
NYSE: BSX

Affected BSX Investor Summary

- **Who:** Boston Scientific Corporation ([NYSE: BSX](#))
 - **What:** Securities fraud class action lawsuit filed
 - **Class Period:** July 23, 2025 through February 3, 2026
 - **Deadline to Seek Lead Plaintiff Status:** May 4, 2026
 - **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's competitive position
 - **Investor Action:** Contact [Kessler Topaz Meltzer & Check, LLP \(www.ktmc.com\)](http://www.ktmc.com) for recovery options
-

The *Boston Scientific Corporation* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Boston Scientific Corporation* ("*Boston Scientific*") (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"). Captioned *John Rudolph Troike v. Boston Scientific Corporation*, No. 26-cv-40075 (D. Mass.), the *Boston Scientific* class action lawsuit alleges that *Boston Scientific* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *Boston Scientific* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than May 4, 2026.

COMPLAINT ALLEGATION SUMMARY:

Boston Scientific develops, manufactures, and markets medical devices, in pertinent part through its Electrophysiology ("EP") business unit that focuses on products used in the detection and treatment of heart rate and rhythm disorders.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) *Boston Scientific* was facing increased competition in the EP market that limited its growth potential; (2) the company's EP segment's growth was unsustainable; and (3) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID BOSTON SCIENTIFIC'S STOCK DROP?

Throughout the latter half of 2025, *Boston Scientific's* management touted that its EP business was not only growing, but that the company also had a "very good understanding of what competition we will face and in what time frame." However, on February 4, 2026, *Boston Scientific* announced that due to new entrants in the market, the company had "lost some share," resulting in disappointing EP sales for 2025, and 2026 guidance that was far below expectations. On this news, Boston Scientific's stock price fell 17.6% in a single day.

THE LEAD PLAINTIFF PROCESS:

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Boston Scientific* common stock during the Class Period to seek appointment as lead plaintiff in the *Boston Scientific* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over \$25 billion for our clients and the classes they represent.

